Abstract RUNX1 encodes a RUNX family transcription factor (TF) and was recently identified as a novel mutated gene in human luminal breast cancers. We found that Runx1 is expressed in all subpopulations of murine mammary epithelial cells (MECs) except the secretory alveolar luminal cells. Conditional knockout of Runx1 in MECs by MMTV-Cre led to a decrease in luminal MECs, largely due to a profound reduction in the estrogen receptor (ER)-positive mature luminal subpopulation, a phenotype that could be rescued by the loss of either Trp53 or Rb1. Mechanistically RUNX1 represses Elf5, a master regulatory TF gene for alveolar cells, and regulates mature luminal TF/co-factor genes (e.g., Foxa1 and Cited1) involved in the ER program. Collectively, our data identified a key regulator of the ER + luminal lineage whose disruption may contribute to the development of ER + luminal breast cancer when under the background of either TP53 or RB1 loss.
Introduction
RUNX1, RUNX2, and RUNX3, and their common non-DNA-binding partner protein CBFβ, form a small family of heterodimeric transcription factors (TFs) referred to as Core-Binding Factors (CBFs) (Speck and Gilliland, 2002) . They are best known as master regulators of cell fate determination in blood, bone, and neuron, respectively (Chuang et al., 2013) . RUNX1 is a master regulator of hematopoietic stem cells and multiple mature blood lineages. Translocations and mutations involving both RUNX1 and CBFB are frequently found in human leukemias (Speck and Gilliland, 2002) . Recently, key roles of this family of TFs in epithelial cells and solid tumors also started to emerge (Taniuchi et al., 2012; Chuang et al., 2013; Scheitz and Tumbar, 2013) . In particular, in breast cancer, recent whole-genome and whole-exome sequencing studies have consistently identified point mutations and deletions of RUNX1 in human luminal breast cancers (Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Ellis et al., 2012) . In addition, mutations in CBFB were also identified in luminal breast cancers from these studies. Its gene product CBFβ is critical for enhancing DNA-binding by RUNX TFs through allosteric regulation (Bravo et al., 2001; Tahirov et al., 2001) . Thus, we hypothesized that RUNX1, together with CBFβ, might play a key role in mammary epithelial cell (MEC) lineage determination as a master regulatory TF and that the loss of this normal function might contribute to breast cancer development.
There are two major epithelial cell lineages in the mammary gland (MG), luminal lineage (including ductal and alveolar luminal cells), and basal lineage (the mature cell type in the basal lineage is myoepithelial cell) ( Figure 1A ). These two types of MECs are produced by multipotent mammary stem cells (MaSCs, which are basal cells) during embryonic development or upon MEC transplantation to cleared mammary fat pads Stingl et al., 2006; Spike et al., 2012) . In adult MGs, they appear to be maintained by both lineage-specific unipotent stem cells and multipotent basal MaSCs, based on lineage tracing studies (Van Keymeulen et al., 2011; van Amerongen et al., 2012; Rios et al., 2014; Tao et al., 2014; Wang et al., 2014) . The gene regulatory network that must be in place to orchestrate lineage specification and differentiation of stem cells into mature MEC types remains largely elusive, although a number of key TFs have been identified in recent years, for example, GATA3 has been shown as a master regulator for both ductal and alveolar luminal cells (KourosMehr et al., 2006; Asselin-Labat et al., 2007) ; ELF5 was identified as a master regulator of alveolar cells (Oakes et al., 2008; Choi et al., 2009) ; SLUG (SNAIL2) was shown as a master regulator of MaSCs, and it could reprogram differentiated MECs to transplantable MaSCs, together with another TF, SOX9 (Guo et al., 2012) . In this work, we asked whether RUNX1 is an integral part of this transcription network and how its mutations contribute to breast tumorigenesis. By using genetic, cellular, and molecular approaches, we found that RUNX1 is a key regulator of estrogen receptor (ER)-positive mature ductal luminal cells, and that the loss of RUNX1 may contribute to the development of ER + luminal breast cancer when under the background of either TP53 or RB1 loss.
Results

Runx1 is expressed in all MEC subsets except in alveolar luminal cells
We first measured expression levels of all three Runx genes and their common co-factor gene Cbfb in freshly sorted basal epithelial cells (Lin − CD24 + CD29 hi ) and luminal epithelial cells (Lin − CD24 + CD29 lo ) ( Figure 1A ) from adult virgin female mice by quantitative RT-PCR (qRT-PCR) . Results showed that Runx1 is the predominantly expressed Runx gene in both luminal and basal cells ( Figure 1B) . Immunohistochemical (IHC) staining further confirmed the expression of RUNX1 protein in these two major MEC types in adult virgin MGs ( Figure 1C) . However, RUNX1 expression is largely absent in alveolar luminal cells (ALs) that start to emerge during pregnancy . In the lactating gland, the only MEC type that still expresses RUNX1 is the myoepithelial cell . Upon involution, RUNX1 expression is restored to a pattern resembling that of the virgin gland ( Figure 1H ). Additionally, we performed microarray expression profiling of sorted subsets of MECs, including basal cells (Lin Several proteins regulate these transformations by switching on and off the expression of genes that are specific to different cell types. Disrupting these proteins can cause the development of cells to go awry and can lead to cancer.
A protein called RUNX1 controls gene expression to direct the development of blood cells. Mutations in the gene encoding this protein have been linked to blood cancers and a particular type of breast cancer, which begins in the cells that line the ducts that carry milk towards the nipple.
Mammary duct-lining cells develop from a pool of stem cells that produces breast tissue cells. Now van Bragt et al. have found that RUNX1 is expressed in the cells lining the ducts of the mammary glands, except those that produce milk. Deleting the gene for RUNX1 in mice reduced the number of duct-lining cells, especially a subgroup of cells that are the sensors for the hormone estrogen. Through experiments on breast cancer cells, van Bragt et al. found that RUNX1 is able to dictate the fate of duct-lining breast cells by controlling other protein regulators. RUNX1 boosts the activity of at least one regulator that encourages the cells to become duct-lining cells and represses another regulatory protein that turns cells into milk-producing cells.
Next, van Bragt et al. found that, in mice lacking the gene for RUNX1, reducing the amounts of certain proteins that normally suppress the formation of tumors restored the populations of estrogen-sensing duct-lining cells. This suggests that mutations in the gene encoding RUNX1, coupled with the loss of a tumor-suppressing protein, may contribute to the development of cancer in the cells that line the breast ducts.
The next challenge is to determine exactly how RUNX1 mutations work together with the loss of the tumor-suppressing protein to drive breast cancer development. This knowledge may translate into new approaches to prevent or treat this type of breast cancer. -Labat et al., 2007 ), or CD14 and c-Kit (Asselin-Labat et al., 2011 ), or CD49b (Li et al., 2009 Shehata et al., 2012) , and is therefore a mixture of overlapping progenitor cell populations and may include common or separate progenitors for ductal and alveolar luminal cells. (B) qRT-PCR analysis of Runx1, Runx2, Runx3, and Cbfb transcripts isolated from luminal and basal cells of adult virgin female mice. (C-H) IHC staining for RUNX1 on sections of MGs at different developmental stages: (C) adult virgin, (D-E) mid-gestation (the region highlighted in D is shown in E), (F-G) lactation (the region highlighted in F is shown in G), and (H) after involution. Arrows and arrowheads indicate RUNX1-expressing luminal and basal cells, respectively; * indicates lumen. Scale bars = 20 μm. [Wagner et al., 1997] ). Estimation of Runx1 levels based on this microarray dataset confirmed its expression in all MEC subsets except in ALs ( Figure 1I ). We examined Runx1 expression levels in different subsets of MECs in several additional published microarray datasets Lim et al., 2010; Meier-Abt et al., 2013) and further confirmed this expression pattern (Figure 1-figure supplement 1A-C) ; in particular, in the pregnant MGs, Runx1 was also found expressed in basal MECs but not in luminal MECs (mainly ALs) (Figure 1-figure supplement 1C) . Lastly, by qRT-PCR, we verified that Runx1 was indeed expressed in sorted LPs and MLs but not in Wap-Cre-marked ALs ( Figure 1J ).
Loss of Runx1 in MECs affects multiple MEC subsets
The RUNX1 mutations identified from the recent sequencing studies of human breast cancers include point mutations, frame-shift mutations, and deletions (Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Ellis et al., 2012) . We analyzed the breast cancer-associated missense mutations of RUNX1 to determine whether they lead to loss-of-function of RUNX1 (Figure 2A ). Based on a previous alanine-scanning site-directed mutagenesis study (Li et al., 2003) , we found that these missense mutations either affect amino acid residues in RUNX1 that directly contact DNA, or disrupt the overall fold of its DNA-binding RUNT domain or abolish its binding to CBFβ, both of which would also perturb its DNA-binding ( Figure 2B ). Thus, similar to RUNX1 deletions, the point mutations also lead to loss-offunction of RUNX1, due to disrupted DNA-binding ability. Therefore, we asked whether and how the loss of Runx1 could affect the development of normal MECs. Runx1 −/− mice died during mid-gestation mainly due to hemorrhages in the central nervous system and are thus not suitable to determine the effect of Runx1-loss on MG development (Okuda et al., 1996; Wang et al., 1996) . We therefore used a conditional knockout allele of Runx1 (Runx1 L/L ) (Li et al., 2006b) . To facilitate characterization of Runx1-null MECs, we bred in a conditional . Cross of the floxed Runx1 mice with the R26Y reporter mice and MMTV-Cre transgenic mice allowed us to simultaneously disrupt Runx1 in MECs and mark the targeted cells by Yellow Fluorescent Protein (YFP) ( Figure 3A) . Lineage analysis revealed that in virgin MGs, MMTV-Cre mainly targeted MECs in the luminal lineage, but it could also lead to Cre-mediated recombination in a portion of basal MECs ( Figure 3B) Figure 3C ). Whole-mount analysis of MGs from MMTV-Cre;Runx1 L/L ;R26Y virgin females or dams on lactation day-0 did not reveal any obvious gross morphological abnormalities, although a portion (3 out of 7) of MMTV-Cre;Runx1 L/L ;R26Y females exhibited a slight delay in expansion of their ductal trees during pubertal growth (Figure 3-figure supplement 1A) . Surprisingly, however, none of the MMTV-Cre;Runx1 L/L ;R26Y dams were able to successfully nurse their pups ( ;R26Y females revealed milk stasis and an increasing number of cytoplasmic lipid droplets (Figure 3-figure supplement 1C) . Similar phenotypes have also been observed in Runx1 conditional knockout mice with Krt14-Cre (i.e., Cre-expressing transgenic mice under the control of the Keratin 14 promoter) (Krt14-Cre;Runx1 L/L , data not shown) and in a number of genetically engineered mice with defects in myoepithelial cell contraction and milk ejection (Li et al., 2006a; Plante et al., 2010; Haaksma et al., 2011; Weymouth et al., 2012) . Since Runx1 is only expressed in myoepithelial cells at this stage ( Figure 1D -G,I, and Figure 1-figure supplement 1C) , we reasoned Figure 3D-E) . Furthermore, the ratios of the YFPmarked luminal to basal subsets were also significantly reduced in MMTV-Cre;Runx1 L/L ;R26Y females ( Figure 3D,F) ; this could be due to an expansion of the YFP-marked basal population or a reduction in the YFP-marked luminal population, or both. However, since the overall population of YFP + MECs in Figure 2 . Analysis of RUNX1 mutations. RUNX1 somatic missense mutations identified in human breast cancers disrupt its DNA-binding either directly (disrupting direct DNA contact) or indirectly (disrupting the overall protein fold of its DNA-binding RUNT domain or disrupting CBFβ binding). (A) RUNX1 full-length protein sequence; RUNT domain is highlighted in blue. The three amino acid residues affected by point mutations in luminal breast cancers (based on Ellis et al. (2012) ) are shown in red. Several additional missense mutations (based on Cancer Genome Atlas Network (2012); Taniuchi et al. (2012) ) are also highlighted with red font. (B) How these missense mutations affect RUNX1 DNA-binding is predicted based on a previous structural and biochemical analysis of the RUNT domain (Li et al., 2003) . DOI: 10.7554/eLife.03881.005
MMTV-Cre;Runx1 L/L ;R26Y females was reduced ( Figure 3D-E) , the reduction in the YFP + luminal/ basal ratio was most likely due to a reduction in the YFP-marked Runx1-null luminal population.
Loss of Runx1 leads to a profound reduction in ER + mature luminal cells
Recent studies suggest that most breast cancers, including both basal-like and luminal subtypes, may originate from luminal cells, rather than from basal MaSCs (Lim et al., 2009; Molyneux et al., 2010; Proia et al., 2011; Keller et al., 2012) . Furthermore, RUNX1 and CBFB mutations have only been found in the luminal subtype of human breast cancers (Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Ellis et al., 2012) and our data so far showed that the loss of Runx1 appeared to lead to a reduction in the luminal population ( Figure 3D-F [Subramanian et al., 2005] ), we observed significant enrichment of a previously generated LP signature and downregulation of a ML signature in Runx1-null luminal cells ( Figure 4A ). These LP and ML signatures were generated previously based on subset-specific genes conserved in the corresponding human and mouse MEC subpopulations (Lim et al., 2010) . Furthermore, we also observed significant enrichment of multiple gene sets related to p53 signaling in Runx1-null luminal , possibly indicating a stress response in these mutant luminal cells in vivo. Lastly, we examined the expression levels of a number of TF/co-factor genes known to be part of the transcription network that regulates specification and maintenance of luminal MECs. In our microarray data, we found that Elf5, a TF gene critically required in the alveolar cell lineage and a LP marker (Oakes et al., 2008; Choi et al., 2009; Lim et al., 2010) , was upregulated in Runx1-null luminal cells, whereas several ductal luminal TF/co-factor genes (e.g., Gata3, Foxa1, Esr1, Cited1) were downregulated ( Figure 4-figure supplement 1B ). Among these luminal TF/co-factor genes, Foxa1 encodes a pioneer factor that is a key determinant of ERα (encoded by Esr1) function (Bernardo et al., 2010; Hurtado et al., 2011) ; Cited1 encodes a selective co-activator for estrogen-dependent transcription, which potentially regulates the sensitivity of luminal cells to estrogen (Yahata et al., 2001; Howlin et al., 2006) . When validated by qRT-PCR, we found that although the expression of Gata3 did not seem to be significantly affected in luminal cells upon Runx1-loss, expression levels of Foxa1, Esr1, and Cited1 were downregulated in Runx1-null luminal cells, whereas Elf5 expression was upregulated ( Figure 4B ).
Our microarray data for the entire luminal population suggested that Runx1-loss in luminal MECs might lead to either a global block in luminal differentiation or loss of a mature luminal MEC subpopulation. (Shehata et al., 2012 Figure 3D-F) , the increase in the ER − LP subpopulation might be mainly due to a reduction in the ER + ML subpopulation (thus proportionally increased the percentage of the ER − LP subset), rather than a significant expansion of ER − LPs
The following source data and figure supplements are available for figure 4: From recent whole-genome/exome sequencing studies, RUNX1 and CBFB mutations were only identified in the luminal subtype of human breast cancers (Banerji et al., 2012; Cancer Genome Atlas Network, 2012; Ellis et al., 2012) , which are typically ER + . Paradoxically our data so far in the murine model suggest that loss-of-function of Runx1 leads to a reduction in ER + luminal MECs in vivo. Furthermore, we have followed MMTV-Cre;Runx1 L/L ;R26Y females for at least 18 months and have not observed any mammary tumor development in them. This can be explained by a possibility in which RUNX1-mutant breast cancer originates from ER + luminal MECs and Runx1 disruption alone actually leads to the loss of the cell-of-origin of such cancer. We hypothesized that additional genetic events might be needed to cooperate with RUNX1-loss to promote the development of luminal breast cancer from ER + luminal MECs. Interestingly, one recent sequencing study unveiled that pathway signatures of RB1 mutation, TP53 mutation, and RUNX1 mutation are co-associated with human luminal B breast tumors . Furthermore, by carefully examining luminal breast cancer cases with RUNX1 mutations, we noticed that >50% of them are accompanied by mutations or deletions in either TP53 or RB1 genes (Cancer Genome Atlas Network, 2012) . Lastly, our microarray data for luminal MECs suggested that loss of Runx1 might lead to activation of the p53 pathway in luminal cells in general (Figure 4-figure  supplement 1A ). Based on these observations, we hypothesized that loss of Runx1 in luminal MECs perturbs the fate of ER + MLs, possibly leading to a stress response and subsequently upregulation of the p53 pathway, which then triggers cell cycle arrest (or apoptosis); this would cause the Runx1-null 
In the resulting compound mice, we were only able to
;R26Y females for ∼4-5 months or ∼9-10 months, respectively, due to lethality possibly caused by hematopoietic malignancies (as MMTV-Cre has leaky expression in bone marrow hematopoietic cells). Nevertheless, we were able to analyze MEC subpopulations in their MGs. Upon MMTV-Cre-induced Trp53 or Rb1 loss alone, the percentages of YFP-marked MECs increased dramatically so that the majority of MECs in their MGs became YFP + ( Figure 5A , increased from ∼20-30% to ∼70-90%), suggesting a growth advantage for Trp53-null or Rb1-null MECs (in relation to their Trp53-WT or Rb1-WT YFP − neighbors). However, the percentages of the YFP-marked luminal population were both reduced ( Figure 5A , middle and bottom left plots compared to upper left plot, green circles). Interestingly, disruption of Runx1 either together with Trp53 or with Rb1 significantly increased the percentages of the YFP + luminal population ( Figure 5A -C, increased from ∼4% [Trp53-loss alone] to ∼11% [Runx1/Trp53-loss] [ Figure 5B ] and from ∼12% [Rb1-loss alone] to ∼23% [Runx1/Rb1-loss] [ Figure 5C ], respectively). Of particular note, the percentage of the YFP-marked ML subpopulation, which was dramatically reduced upon Runx1-loss alone ( Figure 5A , upper right plot, red circle), was reverted back to almost the normal level upon simultaneous loss of Runx1 together with either Trp53 or Rb1 ( Figure 5A, 
RUNX1 controls transcription of select target genes in vitro
Since Runx1-loss leads to a reduction in ER + MLs and the residual MECs present in the CD14 − c-Kit − or CD49b − Sca1 + ML gate appear to have escaped Cre-mediated disruption of Runx1 (Figure 4 , Figure 4-figure supplement 1) , it is technically challenging to study how RUNX1 controls the fate of ER + luminal cells at the molecular level in this mouse model directly. Therefore, we first performed molecular studies in human breast cancer cell lines MCF7 and T47D. Although both cell lines are ER + luminal breast cancer cell lines, a key difference between them at the molecular level is that MCF7 cells express WT p53, whereas T47D cells carry a TP53 missense mutation (nonfunctional p53) (Schafer et al., 2000) . Interestingly, despite multiple attempts, we were only able to obtain RUNX1 knockdown (kd) stable lines from TP53-mutant T47D cells but not from TP53-WT MCF7 cells. This observation suggests that a similar genetic interaction between RUNX1-loss and TP53-loss may also operate in human ER + luminal breast cells. We therefore used T47D cells as our cell line model to study how RUNX1 controls the fate of ER + luminal breast epithelial cells. By Western blot, we found that upon RUNX1 kd, the protein level of ELF5 was increased, whereas the protein levels of both ERα and FOXA1 were reduced, and CITED1 protein level appeared unchanged ( Figure 6A ).
ELF5 is a master regulator of alveolar cells, a cell type in which Runx1 is not expressed ( Figure 1D -J, Figure 1-figure supplement 1C) . Interestingly, it was shown previously that RUNX1 is a direct target of ELF5 and is repressed by it, based on chromatin immunoprecipitation (ChIP) analysis (Kalyuga et al., 2012) . In our microarray data for sorted MEC subsets, as well as those publicly available microarray datasets we analyzed, we could always observe a largely opposite expression pattern of Elf5 and Runx1 ( Figure 1I, Figure 1-figure supplement 1) . In both basal cells and MLs in which Runx1 is highly expressed, Elf5 is not; Elf5 expression is greatly elevated in ALs whereas Runx1 expression is repressed. This negative correlation in their expression levels could be further confirmed in the HC11 cell line model. While both Runx1 and Elf5 were expressed in uninduced HC11 cells, upon induction of alveolar differentiation, the ELF5 protein level was increased, whereas the RUNX1 protein level was reduced (Figure 6-figure supplement 1) . To determine whether ELF5 is also a direct target of RUNX1, we performed ChIP analysis on T47D cells and identified significant binding of RUNX1 to multiple evolutionary conserved RUNX-binding sites in the ELF5 locus ( Figure 6B) . The RUNX1-binding was particularly profound in an enhancer region ∼17 kb upstream of the ELF5 transcription start site (ECR-1, Figure 6B ).
Since RUNX1 kd in T47D cells led to downregulation of ERα and FOXA1 ( Figure 6A ), we asked whether ESR1 (encoding ERα) and FOXA1 are direct targets of RUNX1. We identified a RUNX-binding motif in the ESR1 control region ∼1.4 kb upstream of its transcription start site, as well as several RUNX-binding motifs in the FOXA1 control region ∼1.4-1.9 kb upstream of its transcription start site. By ChIP assay, we confirmed significant binding of RUNX1 to the −1.6 kb and −1.9 kb motifs in the FOXA1 locus ( Figure 6C) . Collectively, these data suggest that FOXA1 and ELF5 genes may be direct targets of RUNX1 positively and negatively regulated by it, respectively.
RUNX1 represses Elf5 and regulates mature luminal TF/co-factor genes involved in the ER program in vivo
To determine whether RUNX1 regulates the expression of these transcription regulators in primary cells in vivo, we took advantage of the rescue of Runx1-null ER + luminal MECs by Trp53 or Rb1-loss ( Figure 5) Figure 7A-B, left plots) , and Foxa1 and Cited1 were downregulated in the rescued double mutant ER + MLs ( Figure 7B , left plot). Since we cannot rule out a possibility in which Rb1-loss in MECs also affects expression of these genes, we compared their expression in double mutants to matched WT females as well. From this comparison, we found that both Elf5 and Esr1 were also upregulated and Foxa1 and Cited1 were slightly downregulated in ER + LPs and ER + MLs from double mutants ( Figure 7A -B, right plots). Furthermore, as we showed above, in MMTV-Cre;Runx1 L/L ;R26Y females, although the YFP-marked ER + MLs appeared to have escaped Cre-mediated disruption of the Runx1 L allele, the YFP-marked ER + LP subset did exhibit a partial reduction in Runx1 expression (Figure 4-figure supplement 1G) . We therefore asked whether there is any correlation of reduced Runx1 expression to changes in expression of other genes in this MEC subset. Interestingly, we found that in Runx1-mutant ER + LPs both Elf5 and Esr1 were upregulated and Foxa1 and Cited1 also appeared slightly upregulated (Figure 7-figure supplement 1A) .
Thus, from both cell line and in vivo expression analyses, the gene that exhibits the most consistent change upon Runx1-loss is Elf5, which appears to be a target gene of RUNX1 repressed by it in ER (Figure 7-figure supplement 1B) . Strikingly, in basal MECs where Elf5 is normally not expressed ( Figure 1I, Figure 1-figure supplement 1) , loss of Runx1 led to its profound upregulation (Figure 7-figure supplement 1B) . These data suggest that in normal MGs, RUNX1 represses expression of Elf5 in almost all MEC subsets in which Runx1 is expressed.
Our in vivo data showed that Esr1 is upregulated rather than downregulated (based on the in vitro data in T47D cells, Figure 6A) Figure 5A ) but also an increase in both the YFP + luminal subset and, in particular,
Research article figure supplement 2A) . In TP53-mutant T47D cells, we found that kd of RUNX1 leads to a significant increase in their proliferation (Figure 7-figure supplement 2B) Figure 7A-B) . Lastly, we found that Esr1 upregulation in vivo appears restricted to the Runx1-null ER + luminal MECs; in ER − LPs and ER − basal MECs, we did not observe upregulation of Esr1 expression upon Runx1 disruption (Figure 7-figure supplement 1C) . This is apparently different from negative regulation of Elf5 by RUNX1, in which loss of Runx1 leads to expression of Elf5 even in basal cells in which Elf5 is normally not expressed (Figure 7-figure supplement 1B) . This is also different from a recent finding of repression of Esr1 by ID4, as loss of Id4 leads to widespread upregulation of Esr1 expression in both luminal and basal MECs (Best et al., 2014) . Collectively, these data suggest that Esr1 is not a direct target repressed by RUNX1 in vivo; the downregulation of ERα in vitro in T47D cells upon RUNX1 kd is likely to be indirect (e.g., due to RUNX1 loss-induced upregulation of ELF5, as overexpression of ELF5 in T47D cells can also suppress ERα expression [Kalyuga et al., 2012] ;R26Y females, Runx1 reduction became more profound in older females. We therefore similarly monitored changes in expression of other TF/co-factor genes over time in animals with the same genotype. This strategy may allow us to control for gene expression changes introduced by differences in cell populations or genetic backgrounds. By using this strategy, we found that in Rb1-null single mutants (controls), Esr1, Foxa1, and Cited1 were upregulated and Elf5 was downregulated in their YFP + CD14 − c-Kit − MLs when they aged; however, in YFP + MLs from double mutants, following Runx1 reduction, although Esr1 was upregulated to a similar level (to that of single mutants), Foxa1 and Cited1 were not, and Elf5 was even further upregulated ( Figure 7C) . We also observed a similar trend of changes for Foxa1, Cited1, and Elf5 in YFP + CD14 + c-Kit + LPs from the same animals ( Figure 7D ). Of note, Esr1 expression in these LPs appeared further upregulated in older females, possibly due to hyperproliferation of the rescued ER + luminal cells within this largely ER − LP subpopulation (the LP subset defined based on CD14 + c-Kit + contains a small number of ER + cells [Shehata et al., 2012] ). Overall, the data from this time course study further supports that in ER + luminal cells, RUNX1 negatively and positively regulates the expression of Elf5 and mature luminal TF/co-factor genes (e.g., Foxa1 and Cited1), respectively.
As shown above, in YFP + ER + LPs from MMTV-Cre;Runx1 L/L ;R26Y females with partial Runx1 reduction, we observed an abnormal expression pattern of these TF/co-factor genes (i.e., upregulation of both Elf5 and Esr1 and slight upregulation of Foxa1 and Cited1, Figure 7-figure supplement 1A) . This may be explained by a possibility in which a portion of them are committed for differentiation to ER + MLs by upregulating Esr1; however due to Runx1-loss, Elf5 is not repressed and Foxa1 is not sufficiently upregulated in them, potentially leading to an abnormal population of Elf5 
Cited1
low expression pattern ( Figure 7C-D) . As a further support to this notion, we measured expression levels of these TF/co-factor genes in the ER − LP, ER + LP, and ER + ML subsets sorted from WT animals and found that Elf5 expression trends down, whereas expression of Esr1, Foxa1, and Cited1 similarly trends up, from ER − LPs to ER + LPs and then to ER + MLs, and that Runx1 expression is also elevated from ER + LPs to ER + MLs (Figure 7-figure supplement 2E ). This expression pattern suggests that differentiation of ER + luminal MECs requires coordinated expression of these factors and Runx1-loss may disrupt their coordinated expression.
Collectively, our in vitro and in vivo expression analyses coupled with ChIP analysis suggest that Elf5 is a key target gene of RUNX1 repressed by it in MECs. RUNX1 also positively regulates the expression of mature luminal TF/co-factor genes involved in the ER program and among them, Foxa1 is a direct target of RUNX1, and RUNX1 does not appear to regulate transcription of Esr1 directly.
Discussion
Among TFs that control cell fates of the two subpopulations of luminal MECs, GATA3 has been shown as a common master regulator for both ER + ductal luminal cells and ER − alveolar luminal cells (KourosMehr et al., 2006; Asselin-Labat et al., 2007) , whereas ELF5 has been identified as a key regulatory TF specific for the alveolar luminal subset (Oakes et al., 2008; Choi et al., 2009) . However, what is the TF that specifically controls the fate of the ER + ductal luminal subset remained largely elusive. In this study, we identified RUNX1 as a key regulator of ER + luminal MECs. RUNX1 controls the in vivo fate of this luminal subpopulation by repressing the program for an alternative cell fate choice (i.e., repressing the key TF gene for alveolar cells, Elf5) and by optimizing activation of the ML gene expression program (i.e., regulating key mature luminal TF/co-factor genes such as Foxa1) ( Figure 8A ). Loss of Runx1 impairs the fate of ER + luminal cells, leading to a profound reduction in this luminal subpopulation. However, the loss of either Trp53 or Rb1 can rescue this defect, leading to hyperproliferation of Runx1-mutant ER + luminal cells, which may eventually progress to ER + luminal breast cancer, upon acquisition of additional mutations ( Figure 8B ). Our study thus provides a direct link between a somatically mutated lineage-specific TF, impaired cell fate, and development of luminal breast cancer.
Among RUNX1 target genes, the repressed Elf5 is of particular interest, as it encodes a master regulatory TF for the alternative cell fate of the milk-secreting alveolar lineage in which Runx1 is not expressed ( Figure 1D-G,I-J) . We showed that ELF5 is a direct target of RUNX1 and is repressed by it ( Figures 6A-B and 7) . Thus, combined with the previous observation in which RUNX1 was reciprocally shown as a direct target repressed by ELF5 (Kalyuga et al., 2012) , these data suggest that RUNX1 and ELF5 are two master regulators for mutually exclusive cell fate choices (i.e., ductal vs alveolar fates) by antagonizing each other's transcription program (e.g., RUNX1 promotes the ER program [this study], whereas ELF5 suppresses it [Kalyuga et al., 2012] ) ( Figure 8A ) in a way similar to the GATA1-PU.1 paradigm for regulating the choice between erythroid and myeloid fates (Huang et al., 2007) .
Intriguingly, RUNX1 not only represses Elf5 expression in ER + luminal cells but also in all other MEC subsets in which Runx1 is expressed (Figure 7-figure supplement 1B) . The de-repression of Elf5 in basal MECs may also be of clinical relevance. Recently it was found that RUNX1 protein expression correlates with poor prognosis in ER − breast cancer and more specifically in triple-negative breast cancer (TNBC) (Ferrari et al., 2014) . Furthermore, RUNX1 was also found associated with superenhancers in an ER − breast cancer cell line (Hnisz et al., 2013) . As super-enhancers often associate with key oncogenes in cancer cells (Loven et al., 2013) , these recent findings suggest that RUNX1 may also play an oncogenic role in ER − breast cancers. The link between RUNX1 and ELF5 in basal MECs may explain a potential oncogenic role of RUNX1 in ER − breast cancer/TNBC, as it was shown previously that SNAI2 (encodes SLUG) is a target of ELF5 repressed by it (Chakrabarti et al., 2012) . Thus, it is possible that RUNX1 expression in ER − breast cancer cells may repress ELF5 expression, leading to de-repression (thus upregulation) of SNAI2 expression, which then promotes epithelial-mesenchymal transition (EMT) and aggressiveness of breast cancer cells. Interestingly, it was shown recently that Snai2-null mice exhibit a nursing defect, due to failed milk ejection caused by defects in basal/myoepithelial cell differentiation (Phillips et al., 2014) . In Runx1-null mice, upregulation of Elf5 in basal MECs may lead to repression of Snai2, which may provide an explanation for the similar nursing defect we have observed in our Runx1 conditional knockout mice (Figure 3-figure supplement 1B-C) .
In luminal breast cancer, our study provides strong evidence to support that RUNX1 plays a key role in this breast cancer subtype as a tumor suppressor in ER + ductal luminal cells, which may be their cells of origin. All three RUNX TFs have been shown to play context-dependent roles in breast cancer development as either tumor suppressors or oncogenes (Chimge and Frenkel, 2013) . Among them, RUNX3 is also a tumor suppressor as it is often inactivated in human breast cancers and loss of one copy of Runx3 led to spontaneous mammary tumor development in a portion of aged female mice (Huang et al., 2012) . The tumor suppressor role of RUNX3 in breast cancer is explained by its ability to inhibit ERα-dependent transactivation by reducing the stability of ERα (Huang et al., 2012) . In contrast, RUNX2 mainly exhibits oncogenic roles in breast cancer by promoting invasiveness and metastasis via its target, SNAI2 (Chimge et al., 2011) ; however it may also play a tumor suppressor role in breast cancer by antagonizing ERα (thus, similar to RUNX3) (Chimge et al., 2012) . In this study, we showed that RUNX1, the most abundantly expressed RUNX TF in MECs, controls the fate of ER + luminal cells in part by upregulating FOXA1 and repressing ELF5. Furthermore, RUNX1 has also been shown as a novel tethering factor for recruiting ERα to its genomic sites for ER-mediating transcriptional activation (Stender et al., 2010) . Estrogen signaling has dual roles in MECs and breast cancer cells; on one hand it has an oncogenic role by promoting proliferation of ER + luminal breast cancer cells, on the other hand it also has a tumor suppressor role by promoting MEC differentiation and inhibiting metastasis of breast cancer cells (Chimge and Frenkel, 2013) . The tumor suppressor role of RUNX2 and RUNX3 mainly relates to the antagonism between RUNX2/3 and the cancer-promoting program of ER signaling, whereas the tumor suppressor role of RUNX1 largely correlates to its ability to positively regulate the tumor-suppression program of ER signaling. The tumor suppressor role of RUNX1 is also consistent with a previous observation in which RUNX1 was found among a 17-gene signature associated with metastasis as a gene downregulated in metastasis-prone solid tumors, including breast cancer (Ramaswamy et al., 2003) .
Lastly, our study also provides an explanation for the paradox in which RUNX1 is a positive regulator of the ER program, yet its loss-of-function mutations and deletions are only present in ER + human luminal breast cancers (often accompanied by mutations or copy number losses in TP53 or RB1 genes) (Cancer Genome Atlas Network, 2012; Ellis et al., 2012) . We show that the loss of Runx1 does not appear to affect transcription of Esr1 directly (thus, the affected luminal cells remain phenotypically ER + ) but may lead to a crippled ER program, in part due to de-repression of Elf5 and insufficient upregulation of Foxa1, which may reduce the sensitivity and output of ER signaling, respectively (Hurtado et al., 2011; Kalyuga et al., 2012) . The impaired ER program in Runx1-mutant ER + luminal cells may cause cellular stress, leading to activation of the p53 pathway and subsequently cell cycle arrest and/or apoptosis; as a result, abnormally differentiated Runx1-mutant ER + luminal cells are outcompeted by their WT neighbors in vivo. However, the loss of Trp53 or Rb1 can relieve the cell cycle arrest or positively activate cell cycle, respectively, and/or rescue apoptosis in them, leading to rescue of the Runx1-mutant ER + luminal cells. In humans, upon acquisition of additional mutations, the RUNX1/TP53-mutant or RUNX1/RB1-mutant ER + premalignant luminal cells may progress to ER + luminal breast cancer, upon acquisition of additional oncogenic events ( Figure 8B ). Of note, germline mutations of RUNX1 that result in haploinsufficiency of RUNX1 can lead to an autosomal dominant disorder referred to as familial platelet disorder with a propensity to acute myeloid leukemia (FPD/AML) (Song et al., 1999) . Interestingly, in one study that characterized three FPD/AML pedigrees, it was found that one female patient with FPD/AML also developed a breast cancer 2 years after AML was diagnosed, and no other tumors were observed in all three pedigrees (Preudhomme et al., 2009) . Although the sample size for this study was too small, it certainly raises an intriguing question as to whether germline mutations of RUNX1 predispose FPD/AML patients to luminal breast cancer, but only under a background of either TP53 or RB1 loss.
In summary, we identified RUNX1 as a key regulator of the ER + luminal lineage. Loss of RUNX1 may contribute to the development of ER + luminal breast cancer under a background of either TP53 or RB1 loss and upon cooperation with other additional oncogenic events.
Materials and methods
Mice
Mice carrying the floxed Runx1 allele (Runx1 L/L ) (Li et al., 2006b) were bred with mice carrying a conditional Cre-reporter, R26Y. Subsequently, these mice were bred with mice that drive expression of Cre recombinase under the control of the mouse mammary tumor virus (MMTV) promoter (MMTV-Cre) and with mice carrying the floxed [Walkley et al., 2008] ). All animal experiments and procedures were approved by our Institutional Animal Care and Use Committee (IACUC).
Whole-mount, histology, and immunohistochemistry
Whole-mounts of MGs of pubertal, adult virgin, or lactation day-0 mice were fixed and processed as previously described (Jones et al., 1996) . For histology and immunohistochemical staining, MGs were fixed in 10% formalin and embedded in paraffin. For RUNX1 or ERα detection, antigen retrieval (Citrate buffer pH 6.0, 20 min boil in microwave oven) was performed prior to incubation with an anti-RUNX1 antibody (2593-1, Epitomics, Burlingame, CA) or an anti-ERα antibody (SC-542, Santa Cruz Biotechnology, Dallas, TX). Signal was detected using the impress reagent kit and DAB substrate (MP-7401 and SK-4100, Vector Laboratories, Burlingame, CA).
Mammary gland cell preparation, flow cytometric analysis, and cell sorting
Thoracic and inguinal mammary glands were dissected from pubertal or adult virgin female mice and cell suspensions were prepared as previously described . Flow cytometric analysis was performed with a DXP11 analyzer (Cytek, Fremont, CA) or an Accuri C6 analyzer (BD Biosciences, San Jose, CA). FACS sorting was performed with a FACSAria sorter (BD Biosciences). Data were analyzed with FlowJo (Tree Star, Ashland, OR) or CFlow (BD Biosciences). Antibodies used for FACS were purchased from eBiosciences (San Diego, Ca) and included CD24-eFluor450, CD24-eFluor605, CD29-APC, CD61-PE, c-Kit-PE-CY7, CD14-PE, CD49b-PE, Sca1-APC and biotinylated CD31, CD45, and TER119 (i.e., lineage [Lin] markers), as well as Streptavidin-PerCP-CY5.5. We also used a Sca1-APC-CY7 antibody purchased from BD biosciences (San Jose, CA). ;R26Y littermates. Normal MEC subsets, including MaSCs, LPs, and MLs, were sorted from WT C57/B6 adult virgin females; alveolar luminal cells (ALs) were sorted as YFP + cells from Wap-Cre;R26Y females at mid-gestation. Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA) was used to generate the expression profiles. All arrays were normalized by dCHIP and analyzed by GSEA as described (Subramanian et al., 2005) , using MSigDB database v3.1 (http://www.broadinstitute.org/gsea/msigdb/ index.jsp). For qRT-PCR, cDNA was generated with Omniscript (Qiagen) according to the manufacture's protocol and real-time PCR was performed using FastStart SYBR Green Master (Roche, Indianapolis, IN). ΔΔCt method was used for normalization to the control group and to the endogenous control (Hprt). Primers are listed in Supplementary file 1.
Microarray analysis and quantitative RT-PCR
ChIP analysis
Cells were cross-linked with 1% formaldehyde at room temperature for 10 min, quenched with 0.125 M glycine for 5 min and washed with PBS, harvested by scraping and lysed in cell lysis buffer (0.1% SDS; 0.5% NP40; 1 mM EDTA; 10 mM Tris-HCl, pH 7.4; 0.5% NaDOC). 200-1000 bp DNA fragments were obtained after sonication. After 10 min centrifugation at max speed at 4°C, supernatant was used for IP overnight at 4°C. 30 μl Dynabeads Protein G beads (Invitrogen, Carlsbad, CA) and 1 μg antibody were used for each IP. One tenth of lysate was saved as input. The following antibodies were used: rabbit anti-RUNX1 (ab92336, Abcam, Cambridge, MA), rabbit IgG (sc-2027, Santa Cruz Biotechnology). The beads were washed twice with the following buffers, 3 min each: low-salt buffer (0.1% SDS; 1% Triton X-100; 1 mM EDTA; 10 mM Tris-HCl, pH 7.4; 300 mM NaCl; 0.1% NaDOC), high-salt buffer (0.1% SDS; 1% Triton X-100; 1 mM EDTA; 10 mM Tris-HCl, pH 7.4; 500 mM NaCl; 0.1% NaDOC), LiCl buffer (10 mM Tris-HCl, pH 8; 0.25M LiCl; 1 mM EDTA, pH 8; 1% NP-40; 1% NaDOC), and TE. Precipitated materials were eluted with 300 μl elution buffer (1% SDS; 0.1 M NaHCO3; 50 mM TrisHCl, pH 8; and 10 mM EDTA). Chromatin was reverse-cross-linked by adding 12 μl of 5 M NaCl and incubated overnight at 65°C. DNA was obtained after RNaseA treatment, protease K treatment, phenol/chloroform extraction, and ethanol precipitation. DNA was analyzed by qPCR, normalized to the input DNA. Primers are listed in Supplementary file 1.
RUNX1 knockdown, Western blot, and proliferation assay shRNAs for RUNX1 were purchased from Open Biosystems (Huntsville, AL; shRNA sequences are listed in Supplementary file 1, data from a pool of TRCN0000013659-D1 and TRCN0000013662-D4 were shown). After lentiviral infection and puromycin selection, stable shRNA-expressing cell lines were generated. For Western blotting, whole-cell extracts were prepared by boiling cells for 10 min at 95°C in SDS sample buffer (50 mM Tris [pH 6.8]; 100 mM DTT; 2% SDS; 0.1% bromophenol blue; 10% glycerol). Cell lysates were then resolved by SDS-PAGE. β-actin (Fisher Lab, Hampton, NH) was used as a loading control. Primary antibodies (RUNX1: Abcam ab92336, ELF5: Abcam ab77007, CITED1: Abcam ab92550, ERα: Santa Cruz Biotechnology sc-8002, FOXA1: Santa Cruz Biotechnology sc-6553) were detected using HRP-conjugated anti-rabbit antibodies and visualized using enhanced chemiluminescence detection (ECL reagents from Fisher Lab). Proliferation of T47D cells was determined by absorbance of alamarBlue, following manufacturer's protocol (Invitrogen Lot155363SA). 1 × 10 5 cells were seeded in a 96-well plate and were measured after 3 or 5 days in culture. 1/10 volume of alamarBlue reagent was directly added to cells in culture medium, incubated for 4 hr at 37°C. Absorbance of alamarBlue was monitored at 570 nm, using 600 nm as a reference wavelength (normalized to the 600 nm value).
Statistical analysis
The results were reported as mean ± S.E.M. unless otherwise indicated, and Student's t tests were used to calculate statistical significance.
Accession numbers
The microarray expression profiling datasets generated in this manuscript have been deposited to the GEO database under the following accession numbers: GSE47375 (for Runx1) and GSE47376 (for normal MEC subsets) or as SuperSeries GSE47377.
Additional files
Supplementary file • Supplementary file 1. Primers and shRNAs used in this study (all sequences from 5′ to 3′). DOI: 10.7554/eLife.03881.020
Major dataset
The following datasets were generated: In the public domain at GEO: http://www.ncbi. nlm.nih.gov/geo/.
